ALK-Abelló A/S

ALK is a global research-driven pharmaceutical company that focuses on prevention, diagnosis and treatment of allergies. ALK has since 1923 been working to improve the quality of life for allergy patients by developing drugs that target the cause of allergy.

ALK is the world leader in allergy immunotherapy - a unique treatment of the cause of allergies. The treatment induces a protective immune response that provides a sustained reduction of allergy symptoms and reduces the risk of developing asthma. ALK provides allergy vaccination injections, sublingual drops and tablets, which is the newest, best documented and most convenient treatment for patients. The portfolio of products also includes JEXT ® - an adrenaline used to treat severe allergic reactions (anaphylactic shock).

ALK invests annually approx. 20% of revenue in research that aims to develop new, evidence-based allergy immunotherapy. Research and development pipeline includes tablet-based allergy vaccines against ragweed, house dust mite, tree pollen and cat allergy. ALK has signed partnership agreements with Merck and Torii Pharmaceutical, concerning the development, registration and commercialization of tablets in Northern America and Japan.

ALK has approx. 1,800 employees with subsidiaries, production facilities and distributors worldwide. The company headquarters is in Denmark and is listed on NASDAQ OMX Copenhagen (OMX: ALK B). The turnover in 2012 was more than DKK 2.3 billion (EURm 314).

Quick facts about ALK Number of employees (2012): 1,855

Turnover (2012): DKK 2,345 million

Operating profit (EBITDA) before special items (2012): DKK 306 million

Research & Development expenses (2012): DKK 511 million

Stock exchange listing: NASDAQ OMX Copenhagen

None declared

No lobbyists with EP accreditations

None declared

None declared

Mr Martin Barlebo (Director, Corporate Communications)

II - In-house lobbyists and trade/professional associations

Companies & groups